Parameter
| Biomarker | HE4 | Full name | Human epididymis protein 4 | Molecular Type | Protein |
|---|---|---|---|---|---|
| Molecular Formula | / | Molecular Weight | / | Core Functional Dimensions | Diagnosis, prognosis |
| Disease | Endometrial Cancer | Disease Subtypes | / | ||
| Organ | Endometrium | Test Sample / Technology Platform | Serum / Plasma (ELISA, electrochemiluminescence method) | ||
| Pathobiological Mechanisms | Abnormally highly expressed during tumor progression, it participates in tumor cell invasion, adhesion and angiogenesis. Its level is related to tumor burden and is involved in cell proliferation, anti-apoptosis and epithelial-mesenchymal transition. It is specifically higher than CA-125 in endometrial cancer. | ||||
| Clinical Availability Status | Clinical recommendation (diagnosis / stratification): Incorporate the endometrial cancer risk assessment model. The AUC for early diagnosis is superior to that of CA-125. | ||||
| Notes and Dynamics | Combined with CA-125 testing, the sensitivity of early diagnosis can be increased to over 85%, and it is applicable for screening of post-menopausal women. | ||||